Doripenem Hydrate (Synonyms: S 4661) |
| Catalog No.GC16675 |
El hidrato de doripenem es un nuevo miembro de la clase de carbapenem de antibiÓticos betalactÁmicos con una cobertura de amplio espectro de patÓgenos anaerÓbicos, grampositivos y gramnegativos.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 364622-82-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Doripenem hydrate is a parenteral, potent, and well-balanced antibiotic against a wide range of both Gram+ and Gram- bacteria including Pseudomonas aeruginosa [1] with MIC90 values of ≤ 0.5 µg/ml against methicillin-susceptible streptococci and staphylococci, 0.032-0.5 µg/ml against members of the family Enterobacteriaceae, Moraxella catarrhalis, and Haemophilus influenza, and 8 µg/ml against Pseudomonas aeruginosa [2].
Patients with cystic fibrosis can be infected with several pathogens such as Haemophilus influenzae, Staphylococcus aureus and P. aeruginosa, chronically. By 18 years of age, 80% of cystic fibrosis patients are infected with P. aeruginosa [3].
Doripenem hydrate was potent against Staphylococcus aureus and Staphylococcus epidermidis with the same MIC90 value of 0.063 µg/ml. Doripenem hydrate was 2-4 times more active than other tested carbapenems against S. aureus. The activity of doripenem hydrate against S. pneumoniae was similar to that of imipenem but higher than that of other tested agents. Doripenem hydrate was potent against S. pneumonia with an activity similar to that of other tested carbapenems (MIC90, 0.5 µg/ml). Doripenem hydrate had an activity similar to that of cefpirome against S. pneumoniae and S. pyogenes. Doripenem hydrate was more active against Enterococcus faecalis than other tested agents except for imipenem [2].
In mice experimentally induced with acute bacteremia, the ED50 of doripenem hydrate against S. aureus Smith was 0.066 mg/kg. Doripenem hydrate was more effective than other tested carbapenems against S. aureus TUH1. Doripenem hydrate was more effective than other tested agents except for meropenem-cilastatin against E. coli C-11. Doripenem hydrate almost shared the same effectiveness with other tested carbapenems against P. aeruginosa E7. Against P. aeruginosa TUH302, doripenem hydrate was the most effective among tested drugs [2].
References:
[1]. Yutaka Nishino, Makoto Kobayashi, Taneyoshi Shinno, et al. Practical Large-Scale Synthesis of Doripenem: A Novel 1â-Methylcarbapenem Antibiotic. Organic Process Research & Development, 2003, 7:846-850.
[2]. Masakatsu Tsuji, Yoshikazu Ishii, Akira Ohno, et al. In Vitro and In Vivo Antibacterial Activities of S-4661, a New Carbapenem. Antimicrobial Agents and Chemotherapy, 1998, 42(1): 94-99.
[3]. Yunhua Chen, Elizabeth Garber, Qiuqu Zhao, et al. In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2005, 49(6):2510-2511.
| Cell experiment [1]: | |
|
Cell lines |
bacteria |
|
Preparation method |
The solubility of this compound in DMSO is >11mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Applications |
S-4661 was potent against methicillin-susceptible Staphylococcus aureus and methicillin-susceptible Staphylococcus epidermidis with the MIC90 of 0.063 μg/ml. S-4661 was potent against penicillin-resistant S. pneumoniae. S-4661 showed activities against S. pyogenes and penicillin-resistant S. pneumoniae. S-4661 was active against Enterococcus faecalis. S-4661 was particularly active against Enterobacteriaceae and H. influenzae. The MIC90s for Escherichia, Klebsiella, Proteus, Providencia, Morganella, Citrobacter, Enterobacter, and Serratia spp. ranged from 0.063 to 0.5 μg/ml. |
| Animal experiment [1]: | |
|
Animal models |
Male SLC/ICR mouse model of bacteremia, mouse model of respiratory tract infection induced by S. pneumonia, male CBA/JNCrj mouse model of pulmonary infection induced by penicillin-resistant S. Pneumonia TUH741 |
|
Dosage form |
Subcutaneously administration, twice daily for 2 days |
|
Application |
The ED50 of S-4661 against S. aureus Smith was 0.066 mg/kg. The ED50 of S-4661 was 0.23 mg/kg against S. pneumonia TUH39, the same as that of imipenem-cilastatin. S-4661 (10 mg/kg) showed significant antibacterial activity. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Tsuji M, Ishii Y, Ohno A, et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem[J]. Antimicrobial agents and chemotherapy, 1998, 42(1): 94-99. | |
| Cas No. | 364622-82-2 | SDF | |
| Sinónimos | S 4661 | ||
| Chemical Name | (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;hydrate | ||
| Canonical SMILES | CC1C2C(C(=O)N2C(=C1SC3CC(NC3)CNS(=O)(=O)N)C(=O)O)C(C)O.O | ||
| Formula | C15H24N4O6S2.H2O | M.Wt | 438.52 |
| Solubility | ≥ 10.96mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2804 mL | 11.402 mL | 22.804 mL |
| 5 mM | 0.4561 mL | 2.2804 mL | 4.5608 mL |
| 10 mM | 0.228 mL | 1.1402 mL | 2.2804 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *